//13 Sep 2011
At the annual French livestock show SPACE, Lallemand Animal Nutrition presents an addition to its probiotic product line Bactocell as from now on it is also available for use in drinking water for poultry and pigs.
The novel product Bactocell Drink is a specific water soluble probiotic formulation consisting of the lactic acid bacteria Pediococcus acidilactici CNCM MA 18/5M. It can be used for broilers, layers, piglets and finishers.
The novel formula allows a speedy intervention and offers flexibility in usage for farm staff as the product can be added directly into the drinking water. Both dosage and moment in time can thus be determined exactly.
In addition, especially in the case of just-weaned piglets, first days post-weaning are full of stress and irregularity – and providing ample amounts of water is paramount in these days. In this case, probiotic supplementation through the water allows the piglet to receive an adapted dose in this first timeframe after weaning. This will lead to an optimised gut flora and provide a healthy start for his growth.
Daily addition of the probiotic through the water gives the assurance that every animal receives the optimal dose of the lactic bacteria.
Lallemand Animal Nutrition can be found at SPACE in Hall 5, Stand D82.
Related websites:
• SPACE
• Lallemand Animal Nutrition
Showing posts with label launches. Show all posts
Showing posts with label launches. Show all posts
14 September 2011
07 July 2011
CP launches first upscale hypermarket in Shanghai
//07 Jul 2011
CP Lotus Corporation, a subsidiary of Thailand's based Charoen Pokphand Group and pioneer of China's hypermarket industry, has partnered with Shanghai-base Shui On group to launch its first upscale food supermarket outlet. Bazaar by Lotus, at Xintiandi Style luxury mall in Shanghai, are offering 7,000 products, 70% of which are imported.
"Bazaar by Lotus is CP's new brainchild that demonstrates the firm's commitment to
create a lasting experience for customers," says Michael Ross, executive vice chairman
of CP Lotus Corp., confident, he says that Bazaar by Lotus will be a great success, given
the growing demand for gourmet foods and the 12.9% growth in China's retail industry
during the first quarter of 2011.
CP Lotus Corporation, a subsidiary of Thailand's based Charoen Pokphand Group and pioneer of China's hypermarket industry, has partnered with Shanghai-base Shui On group to launch its first upscale food supermarket outlet. Bazaar by Lotus, at Xintiandi Style luxury mall in Shanghai, are offering 7,000 products, 70% of which are imported.
"Bazaar by Lotus is CP's new brainchild that demonstrates the firm's commitment to
create a lasting experience for customers," says Michael Ross, executive vice chairman
of CP Lotus Corp., confident, he says that Bazaar by Lotus will be a great success, given
the growing demand for gourmet foods and the 12.9% growth in China's retail industry
during the first quarter of 2011.
13 May 2011
Intervet/SP launches new atrophic rhinitis vaccine for pigs
//12 May 2011
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
28 April 2011
Merial launches offer for Circovac PCV2 vaccine
//22 Apr 2011
Merial Animal Health has launched a cashback offer on its CircovacPCV2 vaccine. The offer represents a £10 discount for every 25 sow dose or 100 piglet dose pack of Circovac purchased by producers from their vet up to the end of July 2011.
Lynda Maris, Circovac brand manager said: “We know that these are tough times for everyone in the industry, and that every little helps. As Circovacis now licensed for piglets as well as sows, along with the cashback this means we can offer profitable PCV2 protection across the whole herd.”
Producers can obtain their cashback voucher when they purchase Circovacfrom their vet. All they need to do is complete the voucher and return it together with proof of purchase to the freepost address provided and they will be directly sent a cheque for their cashback!
PCV2 (Porcine Circovirus Type 2) is widely acknowledged as being one of the greatest problems affecting the pig industry in recent years. Indeed it is estimated to cost up to £468 million per annum across Europe. Furthermore, studies have demonstrated a marked Return on Investment ratio for vaccinating against PCV2 of at least 2.1:1 for piglet vaccination and 4.4:1 for sow vaccination1.
Circovacwas one of the first vaccines to market, and has been successfully used in sows since 2007. In January of 2011 it received a license for use in piglets as well. Ricardo Neto, Merial’s Veterinary Advisor, said: “Studies have shown that using Circovac to vaccinate sows remains the most cost-effective way of protecting the herd against PCV2. However, we recognise that there are circumstances in which piglet, or piglet and sow, vaccination is appropriate. Circovacnow offers the only ‘whole herd’ solution to PCV2, allowing producers and vets to vaccinate piglets, gilts and sows.”
For more information about using Circovac producers should speak to their veterinary surgeon.
Related website: Merial
Merial Animal Health has launched a cashback offer on its CircovacPCV2 vaccine. The offer represents a £10 discount for every 25 sow dose or 100 piglet dose pack of Circovac purchased by producers from their vet up to the end of July 2011.
Lynda Maris, Circovac brand manager said: “We know that these are tough times for everyone in the industry, and that every little helps. As Circovacis now licensed for piglets as well as sows, along with the cashback this means we can offer profitable PCV2 protection across the whole herd.”
Producers can obtain their cashback voucher when they purchase Circovacfrom their vet. All they need to do is complete the voucher and return it together with proof of purchase to the freepost address provided and they will be directly sent a cheque for their cashback!
PCV2 (Porcine Circovirus Type 2) is widely acknowledged as being one of the greatest problems affecting the pig industry in recent years. Indeed it is estimated to cost up to £468 million per annum across Europe. Furthermore, studies have demonstrated a marked Return on Investment ratio for vaccinating against PCV2 of at least 2.1:1 for piglet vaccination and 4.4:1 for sow vaccination1.
Circovacwas one of the first vaccines to market, and has been successfully used in sows since 2007. In January of 2011 it received a license for use in piglets as well. Ricardo Neto, Merial’s Veterinary Advisor, said: “Studies have shown that using Circovac to vaccinate sows remains the most cost-effective way of protecting the herd against PCV2. However, we recognise that there are circumstances in which piglet, or piglet and sow, vaccination is appropriate. Circovacnow offers the only ‘whole herd’ solution to PCV2, allowing producers and vets to vaccinate piglets, gilts and sows.”
For more information about using Circovac producers should speak to their veterinary surgeon.
Related website: Merial
Subscribe to:
Posts (Atom)